CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap
Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused
on developing targeted and immuno-oncology therapeutics, today
announced the Company will be presenting initial data from the
DisTinGuish study, a Phase 2a clinical trial evaluating Leap's
anti-Dickkopf-1 (DKK1) antibody,
DKN-01, in combination with tislelizumab, BeiGene's Ltd.'s
anti-PD-1 antibody, with or without chemotherapy, in patients with
gastric or gastroesophageal junction cancer (G/GEJ), at the
European Society for Medical Oncology (ESMO) Congress, being held
virtually on September 16-21, 2021.
The Company plans to host a conference call on Thursday, September 16, 2021 to further discuss
the data.
"We are pleased to have the opportunity to share initial data
from the DisTinGuish study at ESMO in September," said Douglas E. Onsi, President and Chief Executive
Officer of Leap. "We are encouraged by the potential DKN-01 has to
improve response rates as part of first-line therapy for gastric
and gastroesophageal junction cancer patients, particularly those
patients whose tumors express high levels of DKK1, and look forward to providing additional
details at this year's congress."
Leap Presentation Details:
Title: DKN-01 in combination with tislelizumab and
chemotherapy as a first-line therapy in unselected patients with
advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish
Trial
Abstract Number: 2218
Session type: E-Poster Presentation
Presenter: Samuel J.
Klempner, Harvard Medical
School
Date and time: Thursday, September
16, 2021; 2:30 a.m. ET
About the DisTinGuish Study
The DisTinGuish study (NCT04363801) is a Phase 2a,
non-randomized, open-label, multicenter study of DKN-01 in
combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody,
with or without chemotherapy as first-line or second-line therapy
in adult patients with inoperable, locally advanced gastric or
gastroesophageal junction cancer G/GEJ) adenocarcinoma. The study,
which is being conducted in two parts in the United States and the Republic of Korea,
completed enrollment of 25 patients with first-line G/GEJ cancer in
April 2021 and will enroll up to 48
patients with second-line G/GEJ cancer whose tumors express high
levels of DKK1. Leap is conducting
this combination study as part of an exclusive option and license
agreement with BeiGene for the development of DKN-01 in
Asia (excluding Japan), Australia, and New
Zealand.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing
targeted and immuno-oncology therapeutics. Leap's most advanced
clinical candidate, DKN-01, is a humanized monoclonal antibody
targeting the Dickkopf-1 (DKK1)
protein. DKN-01 is in clinical trials in patients with
esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
Leap has entered into a strategic partnership with BeiGene, Ltd.
for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New
Zealand. For more information about Leap Therapeutics, visit
http://www.leaptx.com or view our public filings with the SEC that
are available via EDGAR at http://www.sec.gov or via
https://investors.leaptx.com/.
RNAscope® is a registered trademark of Advanced Cell
Diagnostics, Inc., Newark, CA,
USA.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. These statements include
Leap's expectations with respect to the development and advancement
of DKN-01, including the initiation, timing and design of future
studies, enrollment in future studies, potential for the receipt of
future option exercise, milestone, or royalty payments from
BeiGene, and other future expectations, plans and prospects.
Although Leap believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to
differ materially from our expectations. Such risks and
uncertainties include, but are not limited to: that the initiation,
conduct, and completion of clinical trials, laboratory operations,
manufacturing campaigns, and other studies may be delayed,
adversely affected, or impacted by COVID-19 related issues; the
accuracy of our estimates regarding expenses, future revenues,
capital requirements and needs for financing; the outcome, cost,
and timing of our product development activities and clinical
trials; the uncertain clinical development process, including the
risk that clinical trials may not have an effective design or
generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; the size and
growth potential of the markets for our drug product candidates;
our ability to continue obtaining and maintaining intellectual
property protection for our drug product candidates; and other
risks. Detailed information regarding factors that may cause actual
results to differ materially will be included in Leap Therapeutics'
periodic filings with the SEC, including Leap's Annual Report on
Form 10-K for the fiscal year ended December
31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap's
Quarterly Reports on Form 10-Q and the other reports Leap files
from time to time with the SEC. Any forward-looking statement
contained in this release speaks only as of its date. Leap
undertakes no obligation to update any forward-looking statement
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Heather Savelle
Investor Relations
Argot Partners
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-esmo-2021-virtual-congress-301340715.html
SOURCE Leap Therapeutics, Inc.